The CNMC is investigating possible anticompetitive practices in the distribution of medicines, medical products, and parapharmacy, involving a commercial strategy to attract and retain pharmacies. Inspections were carried out at a pharmaceutical entity's premises in February 2024 as part of the investigation into potential anticompetitive behavior, which could lead to sanctions under competition law. If anticompetitive practices are confirmed, they may result in fines of up to 10% of the companies' total turnover from the previous year.